Researchers comparing KPV and LL-37 are usually mapping which compound fits a given inflammation and host-defense research question. This is descriptive reference information about how they differ, not guidance or a recommendation. Both are sold strictly for in-vitro laboratory research and are not for human or veterinary use.
| KPV | LL-37 | |
|---|---|---|
| Type | Tripeptide (Lys-Pro-Val), C-terminus of alpha-MSH | 37-residue human cathelicidin fragment |
| Primary research area | Anti-inflammatory NF-κB signaling, mucosal models | Antimicrobial activity, innate-immune signaling |
| Handling | Lyophilized; water-soluble, store frozen | Lyophilized; store frozen, avoid freeze–thaw |
KPV is the short C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory signaling in cell-culture and intestinal-epithelium models.
KPV product page and batch COA · KPV reconstitution guide
LL-37 is the human cathelicidin-derived antimicrobial peptide, studied for direct antimicrobial activity and immunomodulatory signaling.
LL-37 product page and batch COA · LL-37 reconstitution guide
Both are studied in immune contexts but along different axes: KPV in anti-inflammatory signaling, LL-37 in antimicrobial and innate-immune activity. Selection follows the research question, with no comparative human effect claimed.
KPV is a short anti-inflammatory tripeptide from alpha-MSH; LL-37 is a longer antimicrobial peptide from human cathelicidin. Different structures and research contexts.
Some protocols study them alongside each other, but any combination is a decision for the researcher and study design. Nothing here is guidance.
No. Both are sold strictly for in-vitro laboratory research and are not for human or veterinary use.